INHIBITORS

Antibodies to clotting factor are called inhibitors. These antibodies destroy the infused clotting factor before it can control bleeding, making the usual treatment ineffective.

Inhibitor development is one of the most serious and costly complications of Hemophilia, especially in Hemophilia A (Factor VIII). Patients with inhibitors often face more frequent bleeding, increased disability, and higher treatment expenses.

Doctors may suspect inhibitors if:
• Factor treatment does not work properly
• Bleeding becomes more frequent
• Allergic reactions occur during infusion

Inhibitors develop in about:
• 10–20% of people with severe Hemophilia A
• 2–3% of people with Hemophilia B

In some cases, inhibitors may disappear, and research continues to improve treatment options.